Adherence to etanercept therapy in rheumatoid arthritis patients during 3 years of follow-up.
E H VogelzangRenske C F HebingM T NurmohamedA W R van KuijkJ W F KruijffM J l'AmiC L M KrieckaertG WolbinkPublished in: PloS one (2018)
In this study, adherence to etanercept therapy was measured using serum etanercept concentration. In most patients an absent etanercept concentration was due to a medical reason. Furthermore, the majority of patients were adherent to etanercept therapy and had adequate drug exposure. In total, only 12 out of 292 patients (4.1%) were non-adherent during 3 years of follow-up. These findings highlight that only a small minority of patients are non-adherent to etanercept treatment, especially compared to adherence rates of other drugs. However, physicians should be aware that in patients failing to respond to treatment, non-adherence is a possible cause.
Keyphrases
- end stage renal disease
- rheumatoid arthritis patients
- rheumatoid arthritis
- ejection fraction
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- stem cells
- primary care
- ankylosing spondylitis
- type diabetes
- emergency department
- metabolic syndrome
- patient reported outcomes
- bone marrow
- systemic lupus erythematosus
- disease activity
- insulin resistance